Dr. Brian Druker heads the OHSU Knight Cancer Institute. Northwest News Network, Chris Lehman Northwest News Network, Chris Lehman Dr. Brian Druker heads the OHSU Knight Cancer Institute. Northwest News Network, Chris Lehman Researcher ... Oregon Public Broadcasting, 1 week ago
3 images for "brian druker"
MolecularMD Launches NanoString Platform for Multiplexed Digital Evaluation of Gene Expression and Copy Number Variation in Clinical Specimens
- MolecularMD Corp. today announced that it has launched the NanoString nCounter® Analysis System for multiplex biomarker evaluation in support of oncology clinical drug development. Several types of gene panels are offered for clinical trial ...4 Traders, 1 week ago
As cancer cases and deaths shoot up, doctors and patients are outraged by the exorbitant cost of medicines and call for action to be taken. MY Global Trends article last week on the effects of the Trans-Pacific Partnership on access to cancer ...TheStar.com.my, 1 week ago
(Targeted News Service Via Acquire Media NewsEdge) Targeted News Service Targeted News Service ALEXANDRIA, Va., Feb. 27 -- The following federal patents were awarded to inventors in New York. *** Xerox Assigned Patent for Methods and Systems for ...TMC Net, 1 week ago
MolecularMD to Develop Highly Sensitive Companion Diagnostic Test to Support CML Treatment Free Remission Clinical Trials
- MolecularMD Corp. today announced that it has entered into a collaboration with Novartis Pharmaceuticals Corporation to develop a companion diagnostic test to aid in the identification of Ph+ chronic myelogenous leukemia (CML) patients who have ...4 Traders, 3 weeks ago
Big philanthropy came roaring back in 2013, after a handful of years in which the economic downturn lead to the shrinkage of charitable giving. "The amount that [living donors] gave was as much as they gave in the previous two years combined, and ...American Public Media, 4 weeks ago
Ariad Pharmaceuticals, Inc. and Amarin Corporation plc (ADR): Can These Biotechs Bounce Back in 2014
Filed under: Investing Follow @leokornsun In the biotech world, risk-taking investors generally like two kinds of stocks -- speculative ones with huge growth potential and beaten-down ones that have been abandoned due to regulatory actions ...Daily Finance, 1 month ago
BREAKING: WME has minted 20 new partners into the agency fold, and those include the tireless Sundance dealmakers working under WME Global Finance & Distribution chief Graham Taylor. Mark Ankner, Liesl Copland and Alexis Garcia all have made ...Mail.com, 1 month ago
Lorus Therapeutics Inc. has released financial results for the three and six months ended Nov. 30, 2013, and has provided an update on recent accomplishments. Unless specified otherwise, all amounts are in Canadian dollars. The net loss for the ...Stockwatch, 2 months ago Lorus Therapeutics Reports Second Quarter Results for Fiscal 2014 Reuters, 2 months ago (MKTW) Lorus Therapeutics Reports Second Quarter Results for Fiscal 2014 Scottrade, 2 months ago
Blueprint Medicines has just grabbed a new round of cash to help get its first drug candidate into a clinical trial next year. The Cambridge, MA-based company said today that it's completed a $25 million Series B round led by new backer Nextech ...Xconomy, 2 months ago
on your WebpageAdd Widget >Get your members hooked!